Selected publications
-
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results.
Journal of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 7 -
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nature Genetics.
2019
Information Resource
GET IT
Times cited: 156 -
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.
Journal of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 244 -
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Clinical Genitourinary Cancer.
2016
Academic Article
GET IT
Times cited: 14 -
HER2 as a target in invasive urothelial carcinoma.
Cancer Medicine.
2015
Academic Article
GET IT
Times cited: 23 -
Treatment of patients with metastatic urothelial cancer "Unfit" for cisplatin-based chemotherapy.
Journal of Clinical Oncology.
2011
Review
GET IT
Times cited: 203 -
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
The Lancet Oncology.
2011
Information Resource
GET IT
Times cited: 123 -
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design.
Clinical Genitourinary Cancer.
2007
Academic Article
GET IT
Times cited: 34 -
Sunitinib Efficacy Against Advanced Renal Cell Carcinoma.
Journal of Urology.
2007
Academic Article
GET IT
Times cited: 172